Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease. No significant effect on disease progression was seen in a 52-week phase 2clinical trial. In any case, the trial was extended and development of the drug continues. There have been concerns about research misconduct and data fabrication relevant to prasinezumab. As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease. It is under development by Prothena Biosciences and Roche.
